These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. NHLBI Integrated Guidelines on Cardiovascular Disease Risk Reduction: can we clarify the controversy about cholesterol screening and treatment in childhood? de Ferranti SD; Daniels SR; Gillman M; Vernacchio L; Plutzky J; Baker AL Clin Chem; 2012 Dec; 58(12):1626-30. PubMed ID: 22730451 [No Abstract] [Full Text] [Related]
30. [New strategies in treatment of severe hypercholesterolemia in coronary patients: HMG-CoA reductase inhibitors and H.E.L.P.-LDL apheresis]. Thiery J; Seidel D Versicherungsmedizin; 1992 Dec; 44(6):186-92. PubMed ID: 1475888 [TBL] [Abstract][Full Text] [Related]
31. Effectiveness of genetic cascade screening for familial hypercholesterolaemia using a centrally co-ordinated clinical service: an Australian experience. Bell DA; Pang J; Burrows S; Bates TR; van Bockxmeer FM; Hooper AJ; O'Leary P; Burnett JR; Watts GF Atherosclerosis; 2015 Mar; 239(1):93-100. PubMed ID: 25585028 [TBL] [Abstract][Full Text] [Related]
32. A boy with autosomal recessive hypercholesterolaemia. Rodenburg J; Wiegman A; Vissers MN; Kastelein JJ; Stalenhoef AF Neth J Med; 2004 Mar; 62(3):89-93. PubMed ID: 15209474 [TBL] [Abstract][Full Text] [Related]
33. In brief: Zetia and Vytorin: the ENHANCE study. Med Lett Drugs Ther; 2008 Jan; 50(1278):5. PubMed ID: 18219263 [No Abstract] [Full Text] [Related]
34. A pragmatic view of the new cholesterol treatment guidelines. Keaney JF; Curfman GD; Jarcho JA N Engl J Med; 2014 Jan; 370(3):275-8. PubMed ID: 24283199 [No Abstract] [Full Text] [Related]
35. Universal screening and drug treatment of dyslipidemia in children and adolescents. Psaty BM; Rivara FP JAMA; 2012 Jan; 307(3):257-8. PubMed ID: 22174386 [No Abstract] [Full Text] [Related]
36. First case report of familial hypercholesterolemia in an Omani family due to novel mutation in the low-density lipoprotein receptor gene. Al-Hinai AT; Al-Abri A; Al-Dhuhli H; Al-Waili K; Al-Sabti H; Al-Yaarubi S; Al-Hashmi K; Banerjee Y; Al-Zakwani I; Al-Rasadi K Angiology; 2013 May; 64(4):287-92. PubMed ID: 23162007 [TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of coadministration of rosuvastatin, ezetimibe, and colestimide in heterozygous familial hypercholesterolemia. Kawashiri MA; Nohara A; Noguchi T; Tada H; Nakanishi C; Mori M; Konno T; Hayashi K; Fujino N; Inazu A; Kobayashi J; Mabuchi H; Yamagishi M Am J Cardiol; 2012 Feb; 109(3):364-9. PubMed ID: 22112743 [TBL] [Abstract][Full Text] [Related]
38. Inhibition of PCSK9: is this the way forward for managing residual risk? Chowdhury SR; Rees A Curr Opin Lipidol; 2012 Oct; 23(5):509-10. PubMed ID: 22964999 [No Abstract] [Full Text] [Related]
39. Genetic diagnosis of familial hypercholesterolemia in a South European outbreed population: influence of low-density lipoprotein (LDL) receptor gene mutations on treatment response to simvastatin in total, LDL, and high-density lipoprotein cholesterol. Chaves FJ; Real JT; García-García AB; Civera M; Armengod ME; Ascaso JF; Carmena R J Clin Endocrinol Metab; 2001 Oct; 86(10):4926-32. PubMed ID: 11600564 [TBL] [Abstract][Full Text] [Related]
40. Heterozygous familial hypercholesterolemia case study. Friedrich DA J Am Acad Nurse Pract; 2010 Oct; 22(10):523-6. PubMed ID: 21040085 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]